Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major

CMUR > College of Chinese Medicine > School of Chinese Medicine > Journal articles > Item 310903500/2905

Please use this identifier to cite or link to this item: http://ir.cmu.edu.tw/ir/handle/310903500/2905

Title:	Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major
Authors:	巫康熙(Kang-His Wu);張正成(Jeng-Sheng Chang);蔡長海(Chang-Hai Tsai);彭慶添(Ching-Tien Peng)*
Contributors:	中醫學院中醫學系學士班中醫內科學科;中國附醫兒童醫學中心小兒血液腫瘤科
Keywords:	beta-thalassemia major;Heart failure;Deferiprone;Desferrioxamine;Combined therapy
Date:	2004
Issue Date:	2009-08-20 17:57:35 (UTC+8)
Abstract:	Cardiac complications caused by iron deposition are major causes of death in patients with beta-thalassemia major. Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX). Furthermore, combined therapy with L1 and DFX produced an additive or synergistic iron chelating effect. We report the successful treatment of severe heart failure in two patients with beta-thalassemia major with the combined therapy. Magnetic resonance images showed a marked recovery of signal intensity in the heart, indicating a significant reduction of iron load in the heart. No significant adverse effects were noted. Therefore, combined therapy with L1 and DFX should be considered in patients with beta-thalassemia major and cardiac complications.
Relation:	ANNALS OF HEMATOLOGY83(7):471~473
Appears in Collections:	[School of Chinese Medicine] Journal articles

Files in This Item:

File	Size	Format
	0Kb	Unknown	453	View/Open